Search

Displaying results 1941 - 1950 of 8517 in total
  1. Drug

    Ergocalciferol

    go.drugbank.com/drugs/DB00153
    ApprovedInvestigationalNutraceutical

    Ergocalciferol was isolated for the first time from yeast in 1931 and its structure was elucidated in 1932. … [A177637] The first approved product containing ergocalciferol under the FDA records was developed by US Pharm Holdings and was FDA approved in 1941.[L6058]

  2. Drug

    Fezolinetant

    go.drugbank.com/drugs/DB15669
    ApprovedInvestigational

    effective treatments for VMS by relieving symptoms in as many as 95% of menopausal women. … [A259542] Fezolinetant, an NK3 receptor antagonist, was developed in response to this issue as well as more understanding of the role of NK3R in the hypothalamic-pituitary-gonadal (HPG) axis.

  3. Drug

    Terfenadine

    go.drugbank.com/drugs/DB00342
    ApprovedWithdrawn

    In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.

  4. Drug

    Fexinidazole

    go.drugbank.com/drugs/DB12265
    Approved

    [A237555, A237560] Fexinidazole received a positive opinion from the European Medicines Agency (EMA) in November 2018 and was approved by the FDA on July 16, 2021. … Human African trypanosomiasis (HAT, also colloquially referred to as sleeping sickness), caused by _T. brucei gambiense_ and _T. brucei rhodesiense_, remains a moderate risk (>1/10,000 inhabitants per

  5. Drug

    Metharbital

    go.drugbank.com/drugs/DB00463
    ApprovedWithdrawn

    Metharbital is a barbiturate anticonvulsant, similar to phenobarbital, marketed as Gemonil by Abbott Laboratories. It was patented in 1905 by Emil Fischer of Merck.

  6. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.

  7. Drug

    Latanoprostene bunod

    go.drugbank.com/drugs/DB11660
    Approved

    Latanoprostene Bunod has been used in trials studying the treatment of Glaucoma, Ocular Hypertension, Open-Angle Glaucoma, Open Angle Glaucoma, and Intraocular Pressure. … As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution), 0.024% for the indication of reducing intraocular pressure in patients with open-angle glaucoma

  8. Drug

    H3B-8800

    go.drugbank.com/drugs/DB14017
    Investigational

    H3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of acute myelogenous leukemia and chronic myelomonocytic leukemia [L2551]. … It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting [A32749

  9. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    Since 2014, ledipasvir has been available as a fixed dose combination product with [sofosbuvir] (tradename Harvoni) used for the treatment of chronic Hepatitis C. … When combined together, ledipasvir and sofosbuvir as the combination product Harvoni has been shown to achieve a SVR between 93 and 99% after 12 weeks of treatment [FDA Label].

  10. Drug

    Edetate calcium disodium anhydrous

    go.drugbank.com/drugs/DB14598
    ApprovedInvestigational

    [A204173] Edetate calcium disodium was granted FDA approval on 16 July 1953.[L12774]